BTBantayehu Addis Tegegne

Bantayehu Addis Tegegne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bantayehu Addis Tegegne has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Zigale Hibstu Teffera

    Department of Medical Laboratory Science, College of Medicine and Health Sciences Debre Markos University Debre Markos Ethiopia

    7 shared publications
  • Wubetu Yihunie Belay

    Department of Pharmacy, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia

    6 shared publications
  • Desalegn Abebaw

    Department of Medical Laboratory Science, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia

    5 shared publications
  • Habtamu Belew

    Department of Medical Laboratory Science, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia

    5 shared publications
  • Abebe Dagne

    Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia

    4 shared publications
  • Gashaw Azanaw Amare

    Affiliation Department of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia

    4 shared publications

Latest Publications

  • Open Access

    Epigenetic and Metabolic Changes That Drive Trained Immunity in Response to Microbes and Vaccines

    by Desalegn Abebaw, Aytenew Atnaf, Bantayehu Addis Tegegne, Abebe Fenta, Bantegzie Selabat, Temesgen Baylie, Yonatan Kindie, Zigale Hibstu Teffera, Mekuriaw Belayneh, Mohammed Jemal, et al.

    Trained immunity is a form of innate immune memory in which initial exposure to microbial components or vaccines leads to long‐lasting functional reprogramming of innate immune cells through epigenetic and metabolic changes. Unlike adaptive immunity, it does not rely on B or T lymphocytes and provides broad, nonspecific protection against various pathogens. This phenomenon has been observed across a range of immune cells, including monocytes, macrophages, neutrophils, NK cells and even γδ T‐cells, as well as at the level of haematopoietic stem and progenitor cells (HSPCs). Key inducers include microbial products (e.g., β‐glucan, BCG and MMR vaccines), metabolic byproducts (e.g., mevalonate and lactate) and cytokines such as IL‐1β. These agents activate signalling pathways such as the Akt/mTOR/HIF‐1α pathway and lead to chromatin remodelling via histone modifications such as H3K4me3 and H3K9me3. Immunometabolism plays a pivotal role, with trained cells shifting toward glycolysis, glutaminolysis and cholesterol synthesis. Lactate and fumarate further link metabolism to epigenetic remodelling. Notably, trained immunity can be protective in infectious diseases and beneficial in noninfectious contexts, such as cancer immunotherapy and autoimmune regulation. This review provides a comprehensive overview of the cellular, epigenetic and metabolic mechanisms underlying trained immunity, highlighting how innate immune cells acquire memory‐like properties independent of adaptive immunity. This study also provides insights into the therapeutic potential of leveraging trained immunity for vaccine development, infection control and immunomodulation in noninfectious diseases.

  • Open Access

    Exosomes in cancer drug resistance: dual roles in therapy failure and emerging precision therapeutics

    by Bantayehu Addis Tegegne, Habtamu Belew, Zigale Hibstu Teffera, Mekuriaw Belayneh, Desalegn Abebaw, Misganaw Fikrie, Mohammed Jemal, Temesgen Baylie, Fasil Tadesse, Samuel Agegnew Wondm, et al.

    Exosomes play a key role in cancer, functioning both as drivers of drug resistance and as tools for therapy. Tumor-derived exosomes facilitate intercellula

  • Open Access

    Bacterial neonatal sepsis, antimicrobial resistance, and risk factors among neonates in Ethiopia: a systematic review and meta-analysis

    by Habtamu Belew, Bantayehu Addis Tegegne, Yonatan Kindie, Adane Tilahun, Mastewal Yechale Mihret, Zigale Hibstu Teffera, Adane Adugna, Gashaw Azanaw Amare, Desalegn Abebaw, Mekuriaw Belayneh, et al.

    Background: Antimicrobial resistance and bacterial neonatal sepsis are major threats causing high morbidity and mortality among neonates in developing countries, including in Ethiopia. Given the lack of comprehensive and synthesized evidence on the magnitude of the bacterial profile, neonatal sepsis, and antimicrobial resistance among neonates, this systematic review and meta-analysis were initiated to address this gap. Objective: The aim of this meta-analysis aims to assess the prevalence, antimicrobial resistance patterns, and risk factors of neonatal sepsis in Ethiopian neonates. Design: Systematic review and meta-analysis were conducted among Ethiopian neonates. Data source and methods: Preferred reporting item for systematic review and meta-analysis ( PRISMA) was used to screen the identified studies. We conducted a systematic search of various electronic databases including PubMed/MEDLINE, Cochrane Library, African Journals Online (AJOL), Web of Science, Grey literature and Google Scholar. The data were extracted in Microsoft Excel using a standardized data extraction format by two authors. The analysis was carried out with STATA version 17. To detect heterogeneity across studies, the I 2 and the Cochrane Q test statistics were computed. To determine the overall pooled prevalence, a random-effect meta-analysis model was used. This systematic review and meta-analysis were performed according to the updated guidelines, rigorous meta-analytical methodologies to ensure accuracy and reliability. Results: Of 9013 retrieved articles, 20 studies containing 11,754 neonates with a total of 3168 bacterial isolates (837 Gram-positive, 2328 Gram-negative). The predominant bacteria identified were: Klebsiella pneumoniae (1343), Escherichia coli (854), Staphylococcus aureus (356), other Klebsiella spp (234), CoNS (192), Acinetobacter species (172), GBS (164). The overall pooled prevalence of bacterial neonatal sepsis and multi-drug resistance (MDR) were 29.92% (25.79–34.05) and 66.20 (55.43–76.97). The subgroup analysis of this systematic review further revealed that the highest prevalence was observed in Oromia (31.62%) and Amhara (31.56%). The isolated bacteria were more resistant to penicillin groups, cephalosporins, and aminoglycosides. Preterm birth AOR = 8.2, 95%CI: 1.12–15.77), premature rupture of membranes (AOR = 4.8, 95%CI: 3.17–12.77), history of urinary tract infection at antenatal care (AOR = 33.21, 95%; 3.2–63.21), and low birth weight (AOR = 13.73, 95%CI: 4.48–31.95) were significantly associated with bacterial neonatal sepsis. Conclusion: Bacterial neonatal sepsis and MDR have been relatively high. Preterm birth, premature rupture of membranes, history of urinary tract infection at antenatal care, and low birth weight were significantly associated. Implementing antimicrobial stewardship and regular surveillance to control antimicrobial resistance is vital for informing region-specific antibiotic use. Furthermore, early diagnosis and proactive screening for risk factors are key to preventing neonatal sepsis and decreasing its overall burden.


  • Open Access

    Incidence and predictors of mortality among TB-HIV co-infected individuals on anti-tuberculosis and anti-retroviral dual therapy in Northwest Ethiopia: A retrospective cohort study

    by Abebe Fenta, Tebelay Dilnessa, Destaw Kebede, Mekuriaw Belayneh, Zigale Hibstu Teffera, Bewket Mesganaw, Adane Adugna, Wubetu Yihunie Belay, Habtamu Belew, Desalegn Abebaw, et al.

    Background: Co-infection with the human immunodeficiency virus (HIV) and tuberculosis (TB) is a primary cause of death and morbidity. The rate of morbidity and death from TB-HIV is still Ethiopia’s top health issue. Objective: This study aimed to assess the incidence and predictors of mortality among TB-HIV co-infected individuals on anti-TB and anti-retroviral dual Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia. Methods: A retrospective cohort study was conducted at the Debre Markos Comprehensive Specialized Hospital among 436 TB-HIV co-infected individuals. A computer-generated random sampling technique was used to select patient charts registered from September 1st, 2011, and August 31st, 2020. Epi-Data version 3.1 was used for data entry, and STATA version 13 was used for the analysis. The Kaplan-Meier survival curve was applied to estimate the cumulative survival time of the TB-HIV patients. Log-rank tests were utilized to compare the survival time across various categories of explanatory variables. Bi-variable and multivariable Cox proportional hazard models were fitted to find predictors of TB-HIV mortality. Results: The mortality rate of TB-HIV co-infected individuals was 15.6%, with a median survival time of 42 months. Being male (Adjusted hazard Ratio (AHR)1.914;95%CI: 1.022–3.584), having CD4 count < 50 cells/mm3 (AHR 2.699; 95%CI: 1.220–5.973), being ambulatory (HR 2.794;95%CI: 1.459–5.352) and bedridden (AHR 5.514; 95%CI: 2.148–14.156), having low baseline weight (AHR 0.949;95%CI: 0.911–0.989), and having low hemoglobin level (AHR 0.927; 95%CI: 0.441–1.948) were important predictors for mortality. Conclusion and recommendation: The mortality rate among TB-HIV co-infected patients at Debre Markos Comprehensive Specialized Hospital was high. Being male gender, having a CD4 count below 50 cells/mm³, being ambulatory and bedridden, having low baseline weight, and having low hemoglobin were the important predictors of mortality. To reduce mortality, it is crucial to focus on the early identification and management of high-risk patients, particularly those with low CD4 counts, poor functional status, and low hemoglobin. Strengthening integrated TB and HIV care services is recommended to improve patient survival outcomes.


  • Open Access

    The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review

    by Mohammed Jemal, Nuredin Chura Waritu, Temesgen Baylie, Deresse Sinamaw, Enyew Fenta Mengistu, Enatnesh Essa Osman, Gelagey Baye, Bantayehu Addis Tegegne, Gashaw Azanaw Amare, Zigale Hibstu Teffera, et al.

    Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition marked by insulin resistance, decreased insulin production, and persistent low-grade inflammation. The prevalence of T2DM has increased significantly in recent decades; as a result, it is now regarded as one of the fastest-growing public health concerns worldwide. Long-term micro- and macrovascular problems such as nephropathy, retinopathy, neuropathy, and cardiovascular disease can be caused by poor blood glucose control. Therefore, developing reliable diagnostic indicators for early diagnosis and investigating new treatment targets are critical for addressing the increasing prevalence of T2DM. Several novel diagnostic approaches have been created by targeting endogenous proteins, with fetuin-A being one of the most promising targets. Human fetuin-A, also referred to as alpha-2-Heremans Schmid glycoprotein, is a liver-produced glycoprotein that is abundantly secreted into the bloodstream and seems to be involved in insulin resistance, metabolic syndrome, and inflammation. Clinical studies have shown that circulating fetuin-A levels are closely associated with T2DM and its complications, underscoring its potential as both a biomarker and a therapeutic target. This narrative review provides a detailed overview of the evolving role of fetuin-A in the development of T2DM and its associated complications, as well as its future perspectives.


  • Open Access

    Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review

    by Bantayehu Addis Tegegne, Desalegn Abebaw, Zigale Hibstu Teffera, Abebe Fenta, Habtamu Belew, Mekuriaw Belayneh, Mohammed Jemal, Mamaru Getinet, Temesgen Baylie, Fasil Bayafers Tamene, et al.

    The gut microbiome plays a pivotal role in cancer development, progression, and treatment response, driving interest in microbiome‐based interventions. This review examines probiotics, prebiotics, synbiotics, and postbiotics (PPSPs) as precision tools in oncology, highlighting their mechanisms, clinical applications, and challenges. Gut microbiota influence cancer through immune modulation, metabolic regulation, and inflammatory control, while also shaping chemotherapy pharmacokinetics and immunotherapy efficacy. PPSPs demonstrate antitumor effects via: (1) immune activation, (2) intestinal barrier reinforcement, (3) pathogen suppression, and (4) carcinogen neutralization. Clinically, probiotics/postbiotics reduce chemotherapy‐induced mucositis and enhance checkpoint inhibitor responses, while synbiotics/prebiotics selectively nourish beneficial microbes. Despite promise, hurdles like strain‐specific variability, dosing optimization, and individual microbiome differences hinder translation. By integrating preclinical and clinical data, this review underscores PPSPs' potential to bridge gut ecology with antitumor immunity, advancing precision oncology. Future priorities include large‐scale trials, standardized protocols, and mechanistic insights into host‐microbiome‐cancer crosstalk. Personalized microbiota therapies, engineered consortia, and combination regimens represent promising frontiers. With robust evidence, PPSPs may emerge as essential adjuvants, improving outcomes while minimizing toxicity in cancer care.


  • Open Access

    Prevalence and associated factors of childhood sexual abuse in Gashena Town, Ethiopia: A school-based cross-sectional analysis

    by Fikrte Mihret, Bantayehu Addis Tegegne, Mekuriaw Belayneh, Derese Sinamaw Asmare, Yitbarek Wasihun, Melaku Mekonnen Agidew


  • Open Access

    Clinical and biochemical characterization of hepatitis B surface antigen-positive patients with or without Helicobacter pylori co-infection at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia

    by Mekuriaw Belayneh, Bantayehu Addis Tegegne, Mulualem Lemma, Zenahebezu Abay, Yeshambel Belyhun

    Background: Hepatitis B virus (HBV) is a major global public health issue and the most common etiology of chronic liver disease (CLD). The relationship between Helicobacter pylori and HBsAg+ patients was not well investigated and has attracted much scientific and clinical interest, although the relationship remains controversial.Objective: This study aimed to assess the clinical and biochemical characteristics of HBsAg+ liver disease patients with and without H. pylori infection.Methods: From April 1, 2021, to March 30, 2022, a hospital-based cross-sectional study was done at the University of Gondar Comprehensive Specialized Hospital on 384 known HBsAg+ liver disease patients recruited using a convenient sampling technique. All the HBsAg+ patients were tested for fecal H. pylori antigen, and blood specimens were analyzed for ALT, AST, ALP, ALB, TP, BILT, TG, and TChol tests using an automated biochemistry analyzer. GraphPad Prism 8.02 and SPSS 25 were used for data analysis, considering a statistically significant P-value of 0.05.Results: H. pylori co-infection was found in 153 (39.8%) of HBsAg+ study participants. ALT, AST, and total cholesterol mean levels were significantly higher in patients co-infected with H. pylori (pH. pylori co-infected HBsAg+ patients. Our findings showed that H. pylori has a role in the elevation of clinical and biochemical parameters in HBsAg+ liver diseases.


  • Open Access

    Prevalence, antimicrobial susceptibility patterns, and associated risk factors of Enterococci species in healthcare and community settings in Ethiopia: a systematic review and meta-analysis

    by Zigale Hibstu Teffera, Wubetu Yihunie Belay, Bantayehu Addis Tegegne, Abebe Dagne, Ademe Adugnaw, Habtamu Belew, Yasabe Leykun, Samrawit Tefera, Bewket Mesganaw Shtie, Abebe Yenesew, et al.

    Background: Enterococci are significant contributors to healthcare-associated infections in Ethiopia. Objectives: This systematic review and meta-analysis synthesize data on the prevalence, antimicrobial susceptibility patterns, and associated risk factors for Enterococcus infections in Ethiopia Design: Systematic review and meta-analysis Data sources and methods: A comprehensive search was conducted in Scopus, PubMed, Web of Science, Cochrane Library, and Google Scholar, covering studies published in English over the past 5 years, with the last search on October 30, 2024. Inclusion criteria targeted original studies on Enterococcus prevalence, resistance, and risk factors in Ethiopian healthcare and community settings. Risk of bias was evaluated using the ROBINS-I tool. Meta-analytic techniques calculated pooled prevalence, log-adjusted odds ratios (log-AORs), and p -values, accompanied by heterogeneity and subgroup analyses. Results: Thirteen studies encompassing 3598 participants (mean age: 29.26 ± 6.6 years) reported a pooled prevalence of 6.67% (95% CI: 5.50–8.85) for Enterococcus species, with substantial regional variation (0.03–55.88). Major risk factors included prolonged hospital stays (OR = 6), catheterization (OR = 3.5), and diabetes (OR = 3.92). The pooled log-AOR was 0.986 (95% CI: 0.214–1.759; p = 0.01). Antimicrobial susceptibility tests identified cephalexin and co-trimoxazole as the most effective antibiotics (100% sensitivity each), while oxacillin, trimethoprim-sulfamethoxazole, and norfloxacin exhibited the highest resistance rates (85.71%, 80.00%, and 80.00%, respectively). Considerable heterogeneity was observed ( I 2 = 92.31%, τ 2 = 5882.35). Conclusion: This systematic review and meta-analysis found a 6.67% pooled prevalence of Enterococcus infections in Ethiopia, with high variability in antibiotic resistance and key risk factors such as prolonged hospital stays, catheterization, and diabetes. Effective antibiotics included cephalexin and co-trimoxazole, while high resistance was noted for oxacillin and norfloxacin. The findings emphasize the need for targeted infection control and antimicrobial stewardship.


  • Open Access

    Kleinia (Asteraceae): comprehensive review of ethnomedicinal uses, phytochemical profiles, ethnopharmacological applications, and toxicological insights

    by Bantayehu Addis Tegegne, Tesfa Begashaw, Wubetu Yihunie Belay, Mengistie Kassahun Tariku, Tirsit Ketsela Zeleke, Mohammed Jemal, Mamaru Getinet, Agumas Alemu Alehegn, Abebe Dagne

    Kleinia is a genus of over 50 species that are commonly used in primary care in several countries. This study seeks to inspire researchers to quickly discover and isolate the key active metabolites found in Kleinia taxa, thereby promoting the development of novel, safe, and effective therapies for a variety of illnesses. To this end, we performed a thorough search of English-language publications from PubMed, Scopus, ScienceDirect, Web of Science, Google Scholar, and ResearchGate. Our search utilized keywords such as “ethnobotany,” “geographic distribution,” “ethnomedicinal use,” “phytochemistry,” “pharmacological or bioactivities,” and “toxicological activities” related to the genus Kleinia. Chemical structures were depicted using Chemdraw® software. Literature highlights numerous Kleinia taxa used in traditional medicine for conditions like intestinal parasites, measles, smallpox, diabetes, edema, nerve disorders, sexual dysfunction, gastrointestinal issues, cancer and more. Phytochemical analysis identifies 77 secondary metabolites, mainly alkaloids, flavonoids, saponins, terpenes, and terpenoids and other miscellaneous metabolites. Among the Kleinia taxa, K. anteuphorbium, K. longiflora, K. grandiflora, K. odora, K. squarrosa, K. abyssinica, K. pendula, and K. azoides have been scientifically validated to exhibit various pharmacological activities. However, the existence of potentially harmful metabolites in Kleinia taxa, particularly pyrrolizidine alkaloids, emphasizes the significance of cautious application in traditional medicine and the need for rigorous toxicological assessments. In conclusion, this review highlights the promise of Kleinia taxa as significant medicinal resources and advocates for extensive bioprospecting. It encourages global pharmaceutical companies and academic institutions to conduct thorough investigations of the genus Kleinia to uncover new therapeutic possibilities.